We noticed that anti-PD1/PDL1 had been used as neoadjuvant therapy in the documents included in dataset B. The OpACIN trial suggested the feasibility of neoadjuvant combination of ipilimumab and nivolumab for stage III melanoma patients and neoadjuvant therapy expanded more tumor-resident T cell clones than adjuvant application (Blank et al., 2018; Rozeman et al., 2021). Here, PDCD1 is linked to melanoma.